Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Non-Current Deffered Revenue: 2014-2025

Historic Non-Current Deffered Revenue for AC Immune (ACIU) over the last 4 years, with Sep 2025 value amounting to $104.6 million.

  • AC Immune's Non-Current Deffered Revenue rose 5.43% to $104.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.6 million, marking a year-over-year increase of 5.43%. This contributed to the annual value of $104.6 million for FY2025, which is N/A change from last year.
  • As of FY2025, AC Immune's Non-Current Deffered Revenue stood at $104.6 million, which was up 107,640.43% from $97,093 recorded in FY2024.
  • In the past 5 years, AC Immune's Non-Current Deffered Revenue ranged from a high of $104.6 million in FY2025 and a low of $97,093 during FY2024.
  • Its 2-year average for Non-Current Deffered Revenue is $52.4 million, with a median of $52.4 million in 2024.